Rankings
▼
Calendar
ABCL Q4 2019 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena
ABCL
AbCellera Biologics Inc.
$1B
Q4 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
Gross Profit
$0
0.0% margin
Operating Income
-$2M
-61.7% margin
Net Income
-$2M
-51.2% margin
EPS (Diluted)
$-0.01
QoQ Revenue Growth
-7.2%
Cash Flow
Operating Cash Flow
$459,276
Free Cash Flow
-$123,884
Stock-Based Comp.
$112,008
Balance Sheet
Total Assets
$23M
Total Liabilities
$13M
Stockholders' Equity
$10M
Cash & Equivalents
$8M
← FY 2019
All Quarters
Q1 2020 →